CG Oncology Q1 2025 Update: R&D Expenses and Stock Plan Details
Ticker: CGON · Form: 10-Q · Filed: May 13, 2025 · CIK: 1991792
| Field | Detail |
|---|---|
| Company | Cg Oncology, Inc. (CGON) |
| Form Type | 10-Q |
| Filed Date | May 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, R&D Expenses, Employee Stock Plan
TL;DR
CG Oncology Q1 2025 10-Q: R&D spend detailed, ESPP active since Jan '24.
AI Summary
CG Oncology, Inc. filed its quarterly report for the period ending March 31, 2025. The company reported research and development expenses for the first quarter of 2025 and 2024. The filing also references an Employee Stock Purchase Plan established on January 11, 2024, and an Underwriters agreement dated January 29, 2024.
Why It Matters
This filing provides insight into CG Oncology's operational spending on research and development, crucial for a biotech company, and details on employee stock plans which can impact future equity.
Risk Assessment
Risk Level: medium — Biotech companies are inherently risky due to the high failure rate of drug development and regulatory hurdles.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2024-01-11 — Employee Stock Purchase Plan Start Date (Marks the commencement of the company's employee stock purchase plan.)
- 2024-01-29 — Underwriters Agreement Date (Specifies the date related to agreements with underwriters.)
Key Players & Entities
- CG Oncology, Inc. (company) — Filer of the 10-Q report
- March 31, 2025 (date) — End of the reporting period
- January 11, 2024 (date) — Establishment date of the Employee Stock Purchase Plan
- January 29, 2024 (date) — Date of Underwriters agreement
- Kissei Pharmaceut (company) — Mentioned in relation to the company's activities
FAQ
What were CG Oncology's research and development expenses for the first quarter of 2025?
The filing indicates research and development expenses for the period from January 1, 2025, to March 31, 2025, but does not provide the specific dollar amount in the provided text.
When was the CG Oncology Employee Stock Purchase Plan established?
The Employee Stock Purchase Plan was established on January 11, 2024.
What is the fiscal year end for CG Oncology?
CG Oncology's fiscal year ends on December 31.
What is the primary business of CG Oncology?
CG Oncology is in the business of Biological Products (No Diagnostic Substances).
What is the filing date of this 10-Q report?
This 10-Q report was filed on May 13, 2025.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding CG Oncology, Inc. (CGON).